Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial.
Fizazi K, Le Teuff G, Fléchon A, Pagliaro L, Mardiak J, Geoffrois L, Laguerre B, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Cancel M, Juzyna B, Reckova M, Naoun N, Logothetis C, Culine S.
Fizazi K, et al. Among authors: reckova m.
J Clin Oncol. 2024 Aug 21:JCO2301960. doi: 10.1200/JCO.23.01960. Online ahead of print.
J Clin Oncol. 2024.
PMID: 39167741